Thomas A. Hope
YOU?
Author Swipe
View article: Darolutamide plus androgen-deprivation therapy in high-risk biochemical recurrence of prostate cancer (ARASTEP)
Darolutamide plus androgen-deprivation therapy in high-risk biochemical recurrence of prostate cancer (ARASTEP) Open
Patients with prostate cancer treated with radiotherapy (RT) or radical prostatectomy (RP) as primary therapy may develop biochemical recurrence (BCR), which requires effective treatment to delay disease progression. The ARASTEP study (NCT…
View article: Utility of metastasis-directed radiotherapy with and without hormonal therapy in management of oligometastatic prostate cancer
Utility of metastasis-directed radiotherapy with and without hormonal therapy in management of oligometastatic prostate cancer Open
Background Metastasis-directed radiotherapy (MDT) is the mainstay in management of oligometastatic prostate cancer (PCa), and PSMA-PET is currently the most sensitive imaging modality for localizing PCa metastases. The efficacy of MDT guid…
View article: SPARC: The Standardised Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Analysis and Reporting Consensus: A Delphi Analysis
SPARC: The Standardised Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Analysis and Reporting Consensus: A Delphi Analysis Open
SPARC provides a standardised PSMA PET/CT analysis and reporting consensus to serve as a future reference for PSMA PET/CT reporting. Integration of common PSMA PET reporting criteria under one umbrella improves the explanation of imaging f…
View article: Beyond "Not Novel Enough": Enriching Scholarly Critique with LLM-Assisted Feedback
Beyond "Not Novel Enough": Enriching Scholarly Critique with LLM-Assisted Feedback Open
Novelty assessment is a central yet understudied aspect of peer review, particularly in high volume fields like NLP where reviewer capacity is increasingly strained. We present a structured approach for automated novelty evaluation that mo…
View article: 4D‐MRI at 0.55T for internal target volume delineation in liver radiation therapy planning
4D‐MRI at 0.55T for internal target volume delineation in liver radiation therapy planning Open
Background Low‐field MRI provides superior soft‐tissue contrast compared to CT while costing significantly less than high‐field MRI, which makes it a more accessible option for MRI‐guided radiation therapy planning. Four‐dimensional MRI (4…
View article: Assessment of PSMA PET/CT derived predictive markers for <sup>177</sup> Lu-PSMA-617 treatment outcomes: Results from the U.S. Expanded-Access program.
Assessment of PSMA PET/CT derived predictive markers for <sup>177</sup> Lu-PSMA-617 treatment outcomes: Results from the U.S. Expanded-Access program. Open
5079 Background: 177 Lu-PSMA-617 (Lu-PSMA) contributes to prolong progression-free survival (PFS) and overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients who progressed after chemotherapy. Pretherapeut…
View article: In-depth Research Impact Summarization through Fine-Grained Temporal Citation Analysis
In-depth Research Impact Summarization through Fine-Grained Temporal Citation Analysis Open
Understanding the impact of scientific publications is crucial for identifying breakthroughs and guiding future research. Traditional metrics based on citation counts often miss the nuanced ways a paper contributes to its field. In this wo…
View article: Updated Prostate Cancer Risk Groups by Prostate-specific Membrane Antigen Positron Emission Tomography Prostate Cancer Molecular Imaging Standardized Evaluation (PPP2): Results from an International Multicentre Registry Study
Updated Prostate Cancer Risk Groups by Prostate-specific Membrane Antigen Positron Emission Tomography Prostate Cancer Molecular Imaging Standardized Evaluation (PPP2): Results from an International Multicentre Registry Study Open
PPP nomograms were improved in an international multicentre study to predict accurately the 3- and 5-yr overall survival probabilities of prostate cancer. PPP2 yielded superior accuracy to the NCCN risk score. A free software tool has been…
View article: Added Value of Whole-Body Diffusion-Weighted Imaging in Patients Undergoing Prostate-Specific Membrane Antigen Positron Emission Tomography
Added Value of Whole-Body Diffusion-Weighted Imaging in Patients Undergoing Prostate-Specific Membrane Antigen Positron Emission Tomography Open
Background/Objectives: Patients with metastatic castration-resistant prostate cancer (mCRPC) who have Prostate-Specific Membrane Antigen (PSMA)-negative disease have inferior outcomes with radioligand therapy (RLT). The objective of this s…
View article: Safety, Dosimetry, and Feasibility of [<sup>68</sup>Ga]Ga-PSMA-R2 as an Imaging Agent in Patients with Biochemical Recurrence or Metastatic Prostate Cancer
Safety, Dosimetry, and Feasibility of [<sup>68</sup>Ga]Ga-PSMA-R2 as an Imaging Agent in Patients with Biochemical Recurrence or Metastatic Prostate Cancer Open
Prostate-specific membrane antigen (PSMA) is highly expressed in most prostate cancers (PCs). PET and CT imaging studies using 68Ga-labeled PSMA ligands demonstrated the specific localization of 68Ga in PC lesions and distant metastatic le…
View article: How do Humans and Language Models Reason About Creativity? A Comparative Analysis
How do Humans and Language Models Reason About Creativity? A Comparative Analysis Open
Creativity assessment in science and engineering is increasingly based on both human and AI judgment, but the cognitive processes and biases behind these evaluations remain poorly understood. We conducted two experiments examining how incl…
View article: Low- and High-Volume Disease in Metastatic Hormone-Sensitive Prostate Cancer: From CHAARTED to PSMA PET—An International Multicenter Retrospective Study
Low- and High-Volume Disease in Metastatic Hormone-Sensitive Prostate Cancer: From CHAARTED to PSMA PET—An International Multicenter Retrospective Study Open
High-volume disease (HVD) and low-volume disease (LVD) definitions in metastatic hormone-sensitive prostate cancer (mHSPC) patients are based on conventional imaging (CI) (CT/MRI with bone scan [BS]) according to CHAARTED criteria. HVD and…
View article: Implementing evidence‐based strategies for men with biochemically recurrent and advanced prostate cancer: Consensus recommendations from the US Prostate Cancer Conference 2024
Implementing evidence‐based strategies for men with biochemically recurrent and advanced prostate cancer: Consensus recommendations from the US Prostate Cancer Conference 2024 Open
Current US clinical practice guidelines for advanced prostate cancer management contain recommendations based on high‐level evidence from randomized controlled trials; however, these guidelines do not address the nuanced clinical questions…
View article: SNMMI Procedure Standard/EANM Practice Guideline for Fibroblast Activation Protein (FAP) PET
SNMMI Procedure Standard/EANM Practice Guideline for Fibroblast Activation Protein (FAP) PET Open
Contains fulltext : 318481.pdf (Publisher’s version ) (Open Access)
View article: Assessment of response to <scp>PRRT</scp> including anatomical and molecular imaging as well as novel biomarkers
Assessment of response to <span>PRRT</span> including anatomical and molecular imaging as well as novel biomarkers Open
Peptide receptor radionuclide therapy (PRRT) is an effective treatment for both oncological and hormone control and is a widely accepted standard of care treatment for patients with neuroendocrine neoplasms (NEN). Its use is anticipated to…
View article: Efficacy and Toxicity of [<sup>177</sup>Lu]Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: Results from the U.S. Expanded-Access Program and Comparisons with Phase 3 VISION Data
Efficacy and Toxicity of [<sup>177</sup>Lu]Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: Results from the U.S. Expanded-Access Program and Comparisons with Phase 3 VISION Data Open
The phase 3 VISION trial demonstrated that [177Lu]Lu-PSMA-617 prolonged progression-free survival and overall survival (OS) in prostate-specific membrane antigen [PSMA]-positive metastatic castration-resistant prostate cancer (mCRPC) patie…
View article: Assessment of lesion insertion tool in pelvis PET/MR data with applications to attenuation correction method development
Assessment of lesion insertion tool in pelvis PET/MR data with applications to attenuation correction method development Open
Background In modern positron emission tomography (PET) with multi‐modality imaging (e.g., PET/CT and PET/MR), the attenuation correction (AC) is the single largest correction factor for image reconstruction. One way to assess AC methods a…
View article: Impact of Posttreatment SPECT/CT on Patient Management During<sup>177</sup>Lu-PSMA-617 Radiopharmaceutical Therapy
Impact of Posttreatment SPECT/CT on Patient Management During<sup>177</sup>Lu-PSMA-617 Radiopharmaceutical Therapy Open
177Lu can be imaged after administration using SPECT/CT. Most work to date has focused on using posttreatment imaging to measure normal organ and tumor dose. We aimed to assess the impact of posttreatment SPECT/CT on the management of pati…
View article: Pharmacokinetic Comparison of Selective Prostatic Arterial and Intravenous PSMA PET/CT Radioligand Infusions in Primary Prostatic Adenocarcinoma
Pharmacokinetic Comparison of Selective Prostatic Arterial and Intravenous PSMA PET/CT Radioligand Infusions in Primary Prostatic Adenocarcinoma Open
Selective prostatic arterial infusion yielded higher radiotracer uptake in prostatic tumors than intravenous infusions when using dynamic prostate-specific membrane antigen PET/CT to simulate radioligand therapy.
View article: Mechanical processing of wet stored fly ash for use as a cement component in concrete
Mechanical processing of wet stored fly ash for use as a cement component in concrete Open
Wet storage effects on fly ash mean that processing may be necessary to achieve the physical properties required for use in concrete. This paper considers drying, de-agglomeration and milling of various wet stored fly ashes at laboratory a…
View article: Comparison of 18F-DCFPyL and 68Ga-PSMA-11 for 177Lu-PSMA-617 therapy patient selection
Comparison of 18F-DCFPyL and 68Ga-PSMA-11 for 177Lu-PSMA-617 therapy patient selection Open
Purpose 68 Ga-PSMA-11 is recommended for the selection of patients for treatment in the package insert for 177 Lu-PSMA-617. We aimed to compare imaging properties and post-treatment outcomes from radioligand therapy (RLT) of patients selec…
View article: <sup>68</sup>Ga-FAP-2286 PET of Solid Tumors: Biodistribution, Dosimetry, and Comparison with<sup>18</sup>F-FDG
<sup>68</sup>Ga-FAP-2286 PET of Solid Tumors: Biodistribution, Dosimetry, and Comparison with<sup>18</sup>F-FDG Open
Fibroblast activation protein (FAP), expressed in the tumor microenvironment of a variety of cancers, has become a target of novel PET tracers. The purpose of this report is to evaluate the imaging characteristics of 68Ga-FAP-2286, present…
View article: Pathologic outcome of incidentally detected tracer-avid lesions in 68Ga-PSMA-11 PET/CT for prostate cancer
Pathologic outcome of incidentally detected tracer-avid lesions in 68Ga-PSMA-11 PET/CT for prostate cancer Open
Background Prostate-specific membrane antigen (PSMA) PET is effective in identifying prostate cancer metastases. However, PSMA PET uptake has also been described in other lesions, including nonprostate malignancies and benign processes. Pu…
View article: Critical updates in neuroendocrine tumors: Version 9 American Joint Committee on Cancer staging system for gastroenteropancreatic neuroendocrine tumors
Critical updates in neuroendocrine tumors: Version 9 American Joint Committee on Cancer staging system for gastroenteropancreatic neuroendocrine tumors Open
The American Joint Committee on Cancer (AJCC) staging system for all cancer sites, including gastroenteropancreatic neuroendocrine tumors (GEP‐NETs), is meant to be dynamic, requiring periodic updates to optimize AJCC staging definitions. …
View article: Mixed Supervision of Histopathology Improves Prostate Cancer Classification From MRI
Mixed Supervision of Histopathology Improves Prostate Cancer Classification From MRI Open
Non-invasive prostate cancer classification from MRI has the potential to revolutionize patient care by providing early detection of clinically significant disease, but has thus far shown limited positive predictive value. To address this,…